Continuing bevacizumab with second-line chemotherapy for colorectal cancer

Share :
Published: 3 Jun 2012
Views: 5097
Dr Dirk Arnold - University Cancer Center Hamburg, Germany

At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, Dr Dirk Arnold presents results from a phase III clinical trial showing that combination treatment with bevacizumab and standard chemotherapy in the second line setting extends overall survival in patients with advanced colorectal cancer after receiving bevacizumab combination treatment.


ecancerNews Coverage